文献速递消化、代谢与肾脏急症

急诊科急性疼痛患者酮咯酸给药策略的比较有效性

Comparative Effectiveness of Ketorolac Dosing Strategies for Emergency Department Patients With Acute Pain.
PubMed 文献 · Ann Emerg Med · 2023-05-13
一句话结论成人急诊急性疼痛患者,肠外酮咯酸10~20 mg的镇痛效果可能不劣于≥30 mg,低剂量可能不增加不良事件,但可能需要更多补救镇痛。

该系统评价纳入5项随机对照试验(n=627),比较急诊急性疼痛患者低剂量(<30 mg,含10 mg、15~20 mg)与高剂量(≥30 mg)肠外酮咯酸的疗效与安全性。低剂量15~20 mg与高剂量相比,疼痛评分可能无差异(均数差0.05 mm,95%CI -4.91~+5.01 mm,中等确定性);10 mg与高剂量相比也可能无差异(均数差1.58 mm,95%CI -8.86~+5.71 mm,低确定性)。低剂量可能增加补救镇痛需求(RR 1.27,95%CI 0.86~1.87,低确定性),不良事件率可能无差异(RR 0.84,95%CI 0.54~1.33,低确定性)。作者认为成人急诊患者10~20 mg肠外酮咯酸镇痛可能不劣于≥30 mg,但证据受不精确性限制,不能推广至儿童或不良事件高风险人群。

要点

  • 成人急诊急性疼痛患者,肠外酮咯酸15~20 mg与≥30 mg相比疼痛评分可能无差异(均数差0.05 mm,95%CI -4.91~+5.01 mm,中等确定性)。
  • 10 mg与高剂量相比疼痛评分也可能无差异(均数差1.58 mm,95%CI -8.86~+5.71 mm,低确定性)。
  • 低剂量酮咯酸可能增加补救镇痛需求(RR 1.27,95%CI 0.86~1.87,低确定性),但不良事件率可能无差异(RR 0.84,95%CI 0.54~1.33,低确定性)。
  • 证据受不精确性限制,不能推广至儿童或不良事件高风险人群。

适用人群与场景

  • 急诊科急性疼痛成人患者(随机对照试验纳入人群),排除非急诊场景包括术后患者。

研究设计与关键结果

  • 系统评价纳入5项随机对照试验,共627例患者,比较急诊急性疼痛患者肠外酮咯酸低剂量(<30 mg)与高剂量(≥30 mg)的疗效与安全性。
  • 低剂量(15~20 mg)与高剂量(≥30 mg)相比,疼痛评分可能无差异:均数差0.05 mm(100 mm视觉模拟量表,95%CI -4.91~+5.01 mm),中等确定性。
  • 10 mg与高剂量相比,疼痛评分可能无差异:均数差1.58 mm(100 mm视觉模拟量表,95%CI -8.86~+5.71 mm),低确定性。
  • 低剂量酮咯酸可能增加补救镇痛需求:风险比1.27(95%CI 0.86~1.87),低确定性。
  • 低剂量酮咯酸与高剂量相比不良事件率可能无差异:风险比0.84(95%CI 0.54~1.33),低确定性。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入随机对照试验;采用Cochrane偏倚风险2工具评估偏倚风险,采用GRADE方法评估各结局的总体证据确定性。
  • 证据确定性:疼痛评分(15~20 mg vs ≥30 mg)为中等确定性;疼痛评分(10 mg vs ≥30 mg)、补救镇痛需求、不良事件率均为低确定性。
  • 局限:证据受不精确性限制,且不能推广至儿童或不良事件高风险人群。

对床旁实践的改变

  • 作者认为,成人急诊急性疼痛患者肠外酮咯酸10 mg至20 mg在缓解疼痛方面可能不劣于30 mg或更高剂量。
  • 作者认为,低剂量酮咯酸可能对不良事件无影响,但这些患者可能需要更多补救镇痛。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVES: Ketorolac is a commonly used nonopioid parenteral analgesic for treating emergency department (ED) patients with acute pain. Our systematic review aims to summarize the available evidence by comparing the efficacy and safety of differing ketorolac dosing strategies for acute pain relief in the ED.

METHODS: The review was registered on PROSPERO (CRD42022310062). We searched MEDLINE, PubMed, EMBASE, and unpublished sources from inception through December 9, 2022. We included randomized control trials of patients presenting with acute pain to the ED, comparing ketorolac doses less than 30 mg (low dose) to ketorolac doses more than or equal to 30 mg (high dose) for the outcomes of pain scores after treatment need for rescue analgesia, and incidence of adverse events. We excluded patients in non-ED settings, including postoperative settings. We extracted data independently and in duplicate and pooled them using a random-effects model. We assessed the risk of bias using the Cochrane Risk of Bias 2 tool and the overall certainty of the evidence for each outcome using the Grading Recommendations Assessment, Development, and Evaluation approach.

RESULTS: This review included 5 randomized controlled trials (n=627 patients). Low-dose parenteral ketorolac (15 to 20 mg), as compared to high-dose ketorolac (≥30 mg), probably has no effect on pain scores (mean difference 0.05 mm lower on 100 mm visual analog scale, 95% confidence interval [CI] -4.91 mm to +5.01 mm; moderate certainty). Further, low-dose ketorolac at 10 mg may have no effect on pain scores compared to high-dose ketorolac (mean difference 1.58 mm lower on 100 mm visual analog scale, 95% CI -8.86 mm to +5.71 mm; low certainty). Low-dose ketorolac may increase the need for rescue analgesia (risk ratio 1.27, 95% CI 0.86 to 1.87; low certainty) and may have no difference on rates of adverse events (risk ratio 0.84, 95% CI 0.54 to 1.33; low certainty).

CONCLUSION: In adult ED patients with acute pain, parenteral ketorolac given at doses of 10 mg to 20 mg is probably as effective in relieving pain as doses of 30 mg or higher. Low-dose ketorolac may have no effect on adverse events, but these patients may require more rescue analgesia. This evidence is limited by imprecision and is not generalizable to children or those at higher risk of adverse events.

来源:Ann Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Forestell B, Sabbineni M, Sharif S, et al. Comparative Effectiveness of Ketorolac Dosing Strategies for Emergency Department Patients With Acute Pain. Ann Emerg Med. 2023. PMID: 37178102. doi:10.1016/j.annemergmed.2023.04.011

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。